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Gregory L. Moneta, MD, Section EditorFamily Members of Patients with Abdominal Aortic Aneurysms Are at
Increased Risk for Aneurysms: Analysis of 618 Probands and Their
Families from the Liège AAA Family Study
Sakalihasan N, Defraigne JO, Kerstenne MA, et al. Ann Vasc Surg
2014;28:787-97.
Conclusion: Aggregation of AAA in families, particularly among
brothers, provides rational for targeted screening studies in relatives of
patients with AAA.
Summary: Aggregation of AAA in families has been reported since
the 1970’s, with the largest collection of 233 AAA families published in
2003 (Kuivaniemi H et al, J Vasc Surg 2003;37:340-5). Familial clustering
of AAA has also been documented in twin studies (Wahlgren CM et al, J
Vasc Surg 2010;51:3-7). In this study the authors sought to analyze the
results of the Liège AAA Family Study that consists of 618 patients with
unrelated AAA, diagnosed at the University Hospital of Liège. They sought
to answer the following questions: (1) What percentage of patients with
AAA (referred as “AAA probands”) had a positive family history for AAA?
(2) What is the prevalence of AAA among the relatives of AAA probands?
(3) Do familial AAA (FAAA) cases differ from nonfamilial (sporadic) AAA
cases in clinical characteristics? The study consisted of patients with unre-
lated AAA from the period of 1999 and 2012, diagnosed at University
Hospital of Liège Belgium. A detailed family history was obtained from
interviews and recorded using Progeny software. The 618 identiﬁed
patients were divided into 2 study groups; Group I: 296 patients with
AAA (268; 91% men) were followed with computerized tomography com-
bined with positron emission tomography; and Group II: 322 patients
with AAA probands (295; 92% men) whose families were invited to ultra-
sonographic screening. In the initial interviews 62 (10%) of the 618
patients with AAA reported a positive family history for AAA. Ultrasound
screening identiﬁed 24 new AAA’s among 186 relatives ($50 years) of
144 families yielding an AAA prevalence of 13%. The highest prevalence
(25%) was found among brothers. By combining the number of AAA’s
found by ultrasound screening with those diagnosed previously, the
observed lifetime prevalence of AAA was estimated to be 32% in brothers.
The familial AAA cases were more likely to have a ruptured AAA than the
sporadic cases (8% vs 2.4%; P < .0001).
Comment: While we already know there is a genetic component to
AAA etiology, the current data highlights the fact that brothers of AAA
patients are those at highest risk. In fact because of the limitations of inter-
views, the prevalence of AAA among family members and brothers of
patients with AAA may actually be underestimated by this and previous
studies of the genetic component of AAA etiology. Given what appears to
be higher propensity for rupture of familial AAA cases, and the high risk
among brothers, it does seem that the author’s conclusion that targeted
screening of the brothers of patients with AAA is reasonable. In addition,
given the high prevalence among brothers, it seems that the screening for
AAAs in brothers of patients with AAA should not have to wait until the
brother reaches 65 years of age.
Thrombolysis for Pulmonary Embolism and Risk of All-Cause
Mortality, Major Bleeding, and Intracranial Hemorrhage: A
Meta-Analysis
Chatterjee S, Chakraborty A, Weinberg I, et al. JAMA 2014;311:2414-21.
Conclusions: Among patients with pulmonary embolism (PE),
including those who were hemodynamically stable with right ventricular
dysfunction, thrombolytic therapy was associated with lower rates of all-
cause mortality and increased risks of major bleeding and intracranial
hemorrhage.
Summary: It seems logical that thrombolytic therapy may be beneﬁ-
cial in the treatment of some patients with PE. However, to date there has
been no individual study with adequate statistical power to determine
whether thrombolytic therapy is associated with improved survival in com-
parison to conventional anticoagulation. The purpose of the author’s paper
was to perform a meta-analysis to determine the mortality beneﬁts and
bleeding risks associated with thrombolytic therapy compared with1094anticoagulation in acute PE, including the subset of patients hemodynam-
ically stable but with right ventricular dysfunction, so called intermediate-
risk PE. The authors searched PubMed, the Cochrane Library, EMBASE,
EBSCO, Web of Science, and CINAHL databases from their inception
through April 10, 2014. Patients were eligible for inclusion in this
meta-analysis if they were in randomized trials comparing thrombolytic
therapy to standard anticoagulant therapy in PE patients. There were
sixteen trials encompassing 2115 individuals identiﬁed. Eight trials
comprising 1775 patients speciﬁed inclusion of patients with intermedi-
ate-risk PE. The data was independently extracted by two reviewers
and included number of patients, patient characteristics, duration of
follow-up and outcomes. Primary outcomes were all-cause mortality
and major bleeding. Secondary outcomes were risk of recurrent embo-
lism and intracranial hemorrhage (ICH). Peto odds ratio (OR) estimates
and associated 95% CIs were calculated using a ﬁxed-effects model. Use
of thrombolytics was associated with lower all-cause mortality (OR, 0.53;
95% CI, 0.32-0.88; 2.17% [23/1061] vs 3.89% [41/1054] with antico-
agulants. The number needed to treat [NNT] ¼ 59) and greater risks of
major bleeding (OR, 2.73; 95% CI, 1.91-3.91; 9.24% [98/1061] vs
3.42% [36/1054]; number needed to harm [NNH] ¼ 18) and
ICH (OR, 4.63; 95% CI, 1.78-12.04; 1.46% [15/1024] vs 0.19%
[2/1019]; NNH ¼ 78). Major bleeding was not signiﬁcantly increased
in patients 65 years and younger (OR, 1.25; 95% CI, 0.50-3.14).
Thrombolysis was associated with a lower risk of recurrent PE (OR,
0.40; 95% CI, 0.22-0.74; 1.17% [12/1024] vs 3.04% [31/1019];
NNT ¼ 54). In intermediate-risk PE trials, thrombolysis was associated
with lower mortality (OR, 0.48; 95% CI, 0.25-0.92) but more major
bleeding events (OR, 3.19; 95% CI, 2.07-4.92).
Comment: The authors indicate that to the author’s knowledge, this
is the ﬁrst analysis of thrombolysis for treatment of PE that has sufﬁcient
statistical power to detect associations with meaningful mortality reduction,
including hemodynamically stable patients with right ventricular dysfunc-
tion. However, if so, then improvement in mortality must be tempered
by what appears to be signiﬁcantly increased risk of major bleeding and
intracranial hemorrhage with use of thrombolytic therapy for PE, particu-
larly in patients older than 65 years of age.
Vena Cava Filters in Unstable Elderly Patients With Acute Pulmonary
Embolism
Stein PD, Matta F. Am J Med 2014;127:222-5.
Conclusions: Vena cava ﬁlers are associated with a reduced in-hospital,
all-cause case fatality rate in unstable adults with pulmonary embolism (PE),
irrespective of age.
Summary: Data from the Nationwide Inpatient Sample suggest infe-
rior vena cava ﬁlters can be associated with a reduced in-hospital all-cause
fatality rate in unstable patients with acute PE (Stein PD et al, Am J Med
2012;125:478-84). The purpose of this paper was to additionally investigate
whether vena cava ﬁlters are associated with a reduced case fatality rate in
adults of all ages with unstable PE, particularly the elderly.
The authors again utilized the Nationwide Inpatient Sample for their
data. They identiﬁed patients with PE who were unstable (in shock or venti-
lator dependent) from 1999 to 2008 from the Nationwide Inpatient
Sample. There were 21,095 unstable patients with PE who received
thrombolytic therapy. In these patients in-hospital all-cause fatality rate
was lower in every age group who received a vena cava ﬁlter in addition
to thrombolytic therapy (P ¼ .0012 to < .0001). Patients aged
>81 years showed the greatest absolute reduction of case fatality rate
with ﬁlters (19%). Among 50,210 unstable patients who did not receive
thrombolytic therapy, case fatality rate also was lower in every age group
who received a vena cava ﬁlter (all P < .0001). Patients aged $81 years
with vena cava ﬁlters showed the greatest absolute risk reduction of case
fatality rate (27.7%).
Comment: Vena cava ﬁlters remain technology in search of proven
beneﬁt. While administrative databases such as the Nationwide Inpatient
Sample are clearly not perfect, they may provide more useful data then
that from individual case series. This data at least provides some justiﬁcations
for use of vena cava ﬁlters in unstable patients with PE requiring
